ResultsIQ

ResultsIQ › Latest results › Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited Q4 FY26 results press release summary

NSE: GLENMARK · BSE: 532296

Results press release of 29 May 2026, summarised by AI from the filing.

Targeting 2-3 Respiratory product launches in the US and 2-3 in Europe in FY27; RYALTRIS in 8-10 additional markets over the next few quarters.

Key takeaways

  1. Guidance Targeting 2-3 Respiratory product launches in the US and 2-3 in Europe in FY27; RYALTRIS in 8-10 additional markets over the next few quarters.
  2. AbbVie deal IGI secured licensing deal with AbbVie for ISB 2001: USD 700 million upfront, potential total deal value USD 1.925 billion.
  3. Growth driver North America revenue grew 29.4% YoY to ₹9,248 million, aided by deferred out-licensing income recognition for ISB 2001.
  4. Litigation Glenmark USA agreed to settle antitrust lawsuits with state attorneys general for USD 29.628 million over 5 years, subject to court approval.

Original filing on BSE

Glenmark Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹4,018 cr (+23% year on year), EBITDA ₹805 cr (+39% year on year), PAT ₹483 cr (+300% year on year), EBITDA margin 20.0% (+223 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹3,771 cr (+16% year on year), EBITDA ₹763 cr (+36% year on year), PAT ₹301 cr (+100% year on year), EBITDA margin 20.2% (+300 bps). Score 47 of 100, In line with trend. Revenue, EBITDA and profit before exceptional items growth were in line with the company's own trend. EBITDA margin rose 300 bps year on year. Other income 49% of PBT. Consolidated profit +7433% but standalone -150%. Revenue fell 3% from last quarter. Share price after the results: −5.3% in 27 days (Nifty 500: +2.0%).
  • Q3 FY26: Revenue ₹3,901 cr (+15% year on year), EBITDA ₹870 cr (+45% year on year), PAT ₹403 cr (+58% year on year), EBITDA margin 22.3% (+459 bps). Score 49 of 100, In line with trend. Revenue, EBITDA and profit before exceptional items growth were in line with the company's own trend. EBITDA margin rose 459 bps year on year. Consolidated profit +16% but standalone -32%. Revenue fell 35% from last quarter. Share price after the results: +10.1% in 28 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹6,047 cr (+76% year on year), EBITDA ₹2,358 cr (+292% year on year), PAT ₹610 cr (+300% year on year), EBITDA margin 39.0% (+1,000 bps). Score 95 of 100, Above trend. Revenue, EBITDA and profit before exceptional items growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Tax rate 37%. Consolidated profit +72% but standalone -224%. Revenue grew on the previous quarter, against its usual seasonal pattern. Profit before exceptional items rose ₹1,879 cr on a year ago, more than the ₹272 cr it added the year before. Share price after the results: +4.2% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹3,264 cr (+1% year on year), EBITDA ₹581 cr (−1% year on year), PAT ₹47.0 cr (−9% year on year), EBITDA margin 17.8% (−36 bps). Score 36 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were in line with the company's own trend. EBITDA margin fell 36 bps year on year. Other income 27% of PBT. Tax rate 50%. Share price after the results: +4.3% in 29 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹3,256 cr (+6% year on year), EBITDA ₹561 cr (+11% year on year), PAT ₹4.0 cr (−61% year on year), EBITDA margin 17.2% (+74 bps). Score 38 of 100, Below trend. Revenue and EBITDA growth were in line with the company's own trend; profit before exceptional items growth was below it. EBITDA margin rose 74 bps year on year. Other income 150% of PBT. Tax rate 38%. Revenue fell 4% from last quarter. Share price after the results: +15.2% in 28 days (Nifty 500: +1.1%).
  • Q3 FY25: Revenue ₹3,388 cr (+35% year on year), EBITDA ₹600 cr, PAT ₹348 cr, EBITDA margin 17.7% (+1,000 bps). Score 91 of 100, Above trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year.
  • Q2 FY25: Revenue ₹3,434 cr (+7% year on year), EBITDA ₹602 cr (+31% year on year), PAT ₹354 cr, EBITDA margin 17.5% (+316 bps). Score 64 of 100, In line with trend. EBITDA margin rose 316 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Glenmark Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.